Hixon Zuercher LLC Trims Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Hixon Zuercher LLC lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 9,148 shares of the life sciences company’s stock after selling 165 shares during the quarter. Hixon Zuercher LLC’s holdings in Illumina were worth $1,222,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after buying an additional 48,018 shares during the period. Primecap Management Co. CA lifted its holdings in shares of Illumina by 3.6% in the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after buying an additional 87,599 shares during the period. Janus Henderson Group PLC raised its holdings in Illumina by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after purchasing an additional 625,245 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Illumina by 4.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock valued at $164,334,000 after buying an additional 54,319 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after buying an additional 631,294 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Trading Up 1.0 %

Illumina stock opened at $133.01 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The firm’s fifty day moving average price is $139.05 and its 200 day moving average price is $135.05. Illumina, Inc. has a 12-month low of $100.08 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.33 EPS. Analysts anticipate that Illumina, Inc. will post 4.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several recent analyst reports. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a research note on Thursday, October 17th. Barclays boosted their price target on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. UBS Group boosted their target price on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Royal Bank of Canada increased their target price on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Finally, HSBC raised Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. Eight investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Illumina presently has an average rating of “Moderate Buy” and an average price target of $165.63.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.